Journal of Emergency Practice and Trauma

The pattern and characteristics of acute coronary events in patients after percutaneous coronary intervention (PCI)

Document Type : Original Article

Authors

Ata Firouzi 1
Alireza Raji Amir Hasani 2
naemeh Bahrami 1
Parnian Bahrami 3

1 Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran, Iran

2 Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

3 School of Psychology, Deakin University, Melbourne, Australia

https://doi.org/10.34172/jept.2025.13
Abstract
Objective: While PCI achieves high procedural success rates, persistent risks such as periprocedural thrombosis, inflammatory cascades, and myocardial hypoperfusion contribute to a bimodal pattern of early and late complications, underscoring gaps in current risk prediction models. This research focuses on identifying the risk factors contributing to recurrent coronary events, particularly stent thrombosis and in-stent restenosis, in patients admitted to the cardiac emergency department.
Methods: A retrospective cohort study was conducted on 204 patients at Shahid Rajaei Hospital to analyze their clinical records, including demographic data, cardiovascular risk factors, and treatment history. Data collection utilized a structured checklist encompassing demographics, cardiovascular risk factors, treatment history, procedural details, and outcomes. Statistical analyses (PRISM version 9.0) included descriptive statistics and multivariable logistic regression to assess predictors of outcomes.
Results: Multivariate logistic regression analysis revealed that for same-artery re-involvement, the duration after first myocardial infarction was significantly associated with increased risk (P < 0.0001, OR = 3.666). Regarding stent thrombosis, multiple factors including duration after myocardial infarction (P < 0.001), not taking Plavix (P = 0.033), MI type (P = 0.001), diabetes mellitus (P = 0.002), cigarette smoking (P = 0.029), and absence of family history (P = 0.03) all demonstrated significant effect. For in-stent restenosis, only the absence of diabetes (P = 0.018, OR = 0.432) was significantly associated with decreased likelihood of this outcome.
Conclusion: The study also emphasizes the importance of early detection, regular follow-ups, and effective management strategies, such as pharmacological intervention and lifestyle changes, to reduce the risk of adverse cardiac outcomes. Additionally, it was found that a prolonged duration since the initial myocardial infarction significantly elevates the risks of same-artery re-occlusion and stent thrombosis.

Keywords

Percutaneous coronary intervention (PCI)
Acute coronary syndrome
Heart disease risk factors
Angioplasty
Subjects
1. Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, et al. ST-segment elevation myocardial infarction. Nat Rev Dis Primers. 2019;5(1):39. doi: 10.1038/s41572-019-0090-3.
2. Pascual I, Avanzas P, Almendárez M, Lorca R, Vigil-Escalera M, Arboine L, et al. STEMI, primary percutaneous coronary
intervention and recovering of life expectancy: insights from the SurviSTEMI study. Rev Esp Cardiol (Engl Ed).
2021;74(10):829-37. doi: 10.1016/j.rec.2020.08.008.
3. Nafasi L, Rahmani R, Shafiee A, Salari A, Abdollahi A, Meysamie A. Can a high reloading dose of atorvastatin prior
to percutaneous coronary intervention reduce periprocedural myocardial infarction? Curr Med Res Opin. 2014;30(3):381-6.doi: 10.1185/03007995.2013.834249.
4. Sawano M, Kohsaka S, Ishii H, Numasawa Y, Yamaji K, Inohara T, et al. One-year outcome after percutaneous coronary intervention for acute coronary syndrome - an analysis of 20,042 patients from a Japanese nationwide registry. Circ J.2021;85(10):1756-67. doi: 10.1253/circj.CJ-21-0098.
5. Fanaroff AC, Zakroysky P, Wojdyla D, Kaltenbach LA, Sherwood MW, Roe MT, et al. Relationship between operator
volume and long-term outcomes after percutaneous coronary intervention. Circulation. 2019;139(4):458-72. doi: 10.1161/circulationaha.117.033325.
6. Clare J, Ganly J, Bursill CA, Sumer H, Kingshott P, de Haan JB. The mechanisms of restenosis and relevance to next
generation stent design. Biomolecules. 2022;12(3):430. doi:10.3390/biom12030430.
7. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction.
Eur Heart J. 2016;37(13):1024-33. doi: 10.1093/eurheartj/ehv484.
8. Ganesha Babu G, Malcolm Walker J, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous
coronary intervention: an important target for cardioprotection. Eur Heart J. 2011;32(1):23-31. doi:10.1093/eurheartj/ehq393.
9. Mangiacapra F, Bressi E, Di Gioia G, Pellicano M, Di Serafino L, Peace AJ, et al. Coronary microcirculation and periprocedural myocardial injury during elective percutaneous coronary intervention. Int J Cardiol. 2020;306:42-6. doi:
10.1016/j.ijcard.2019.12.042.
10. Nakano M, Yahagi K, Otsuka F, Sakakura K, Finn AV, Kutys R, et al. Causes of early stent thrombosis in patients
presenting with acute coronary syndrome: an ex vivo human autopsy study. J Am Coll Cardiol. 2014;63(23):2510-20. doi:
10.1016/j.jacc.2014.02.607.
11. Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, et al. Consistent reduction in periprocedural
myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (Cangrelor
Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation. 2016;134(10):723-33. doi:
10.1161/circulationaha.115.020829.
12. Pfoh ER, Hamilton A, Hu B, Stilphen M, Rothberg MB. The sixclicks mobility measure: a useful tool for predicting discharge disposition. Arch Phys Med Rehabil. 2020;101(7):1199-203. doi: 10.1016/j.apmr.2020.02.016.
13. Moscucci M, Kline-Rogers E, Shareet al D. Simple bedside additive tool for prediction of in-hospital mortality after
percutaneous coronary interventions. ACC Curr J Rev. 2002;11(1):59. doi: 10.1016/s1062-1458(01)00578-5.
14. Wang J, Wang S, Zhu MX, Yang T, Yin Q, Hou Y. Risk prediction of major adverse cardiovascular events occurrence
within 6 months after coronary revascularization: machine learning study. JMIR Med Inform. 2022;10(4):e33395. doi:
10.2196/33395.
15. Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, et al. Residual ischemic risk and its determinants in patients
with previous myocardial infarction and without prior stroke or TIA: insights from the REACH registry. Clin Cardiol.
2016;39(11):670-7. doi: 10.1002/clc.22583.
16. Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, et al. Cardiovascular events and death after myocardial infarction
or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391-9. doi: 10.1002/clc.23160.
17. Lee SH, Jeong MH, Ahn JH, Hyun DY, Cho KH, Kim MC, et al. Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention. Korean J Intern Med. 2022;37(4):777-85. doi: 10.3904/kjim.2021.427.
18. Nair R, Johnson M, Kravitz K, Huded C, Rajeswaran J, Anabila M, et al. Characteristics and outcomes of early recurrent myocardial infarction after acute myocardial infarction. J Am Heart Assoc. 2021;10(16):e019270. doi: 10.1161/
jaha.120.019270.
19. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36(47):3320-31. doi: 10.1093/eurheartj/ehv511.
20. Doyle B, Rihal CS, O’Sullivan CJ, Lennon RJ, Wiste HJ, Bell M, et al. Outcomes of stent thrombosis and restenosis
during extended follow-up of patients treated with baremetal coronary stents. Circulation. 2007;116(21):2391-8. doi:
10.1161/circulationaha.107.707331.
21. Miyazaki Y, Suwannasom P, Sotomi Y, Abdelghani M,Tummala K, Katagiri Y, et al. Single or dual antiplatelet therapy
after PCI. Nat Rev Cardiol. 2017;14(5):294-303. doi: 10.1038/nrcardio.2017.12.
22. Zwart B, Godschalk TC, Kelder JC, Ten Berg JM. High risk of stent thrombosis in the first 6 months after coronary stenting: do not discontinue clopidogrel early after ACS. J Interv Cardiol. 2017;30(5):421-6. doi: 10.1111/joic.12413.
23. Nusca A, Piccirillo F, Bernardini F, De Filippis A, Coletti F, Mangiacapra F, et al. Glycaemic control in patients undergoing percutaneous coronary intervention: what is the role for the novel antidiabetic agents? A comprehensive review of basic science and clinical data. Int J Mol Sci. 2022;23(13):7261.doi: 10.3390/ijms23137261.
24. Triggle CR, Ding H, Marei I, Anderson TJ, Hollenberg MD. Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease. Can J Physiol Pharmacol. 2020;98(7):415-30. doi: 10.1139/cjpp-2019-0677.
25. Sivagangailakshmi V, Rajkumar D. Effects of cigarette smoking on coagulation profile among smokers. Int Arch Integr Med. 2017;4(8):116-20.
26. Pujani M, Chauhan V, Singh K, Rastogi S, Agarwal C, Gera K. The effect and correlation of smoking with platelet indices, neutrophil lymphocyte ratio and platelet lymphocyte ratio. Hematol Transfus Cell Ther. 2021;43(4):424-9. doi: 10.1016/j.htct.2020.07.006.
27. Chen T, Li W, Wang Y, Xu B, Guo J. Smoking status on outcomes after percutaneous coronary intervention. Clin
Cardiol. 2012;35(9):570-4. doi: 10.1002/clc.22004.
28. Xia J, Li Q, Liu Y, Ren Q, Gao J, Tian Y, et al. A GLP-1 analog liraglutide reduces intimal hyperplasia after coronary
stent implantation via regulation of glycemic variability and NLRP3 inflammasome/IL-10 signaling in diabetic swine. Front Pharmacol. 2020;11:372. doi: 10.3389/fphar.2020.00372.
29. Ferraro RA, van Rosendael AR, Lu Y, Andreini D, Al-Mallah MH, Cademartiri F, et al. Non-obstructive high-risk plaques increase the risk of future culprit lesions comparable to obstructive plaques without high-risk features: the ICONIC study. Eur Heart J Cardiovasc Imaging. 2020;21(9):973-80.
doi: 10.1093/ehjci/jeaa048.
30. Jakubiak GK, Pawlas N, Cieślar G, Stanek A. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int J Environ Res Public Health. 2021;18(22):11970.doi: 10.3390/ijerph182211970.
31. Ullrich H, Olschewski M, Münzel T, Gori T. Coronary instent restenosis: predictors and treatment. Dtsch Arztebl Int.
2021;118(38):637-44. doi: 10.3238/arztebl.m2021.0254.
32. Wang JL, Qin Z, Wang ZJ, Shi DM, Liu YY, Zhao YX, et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol. 2018;15(2):137-45. doi: 10.11909/j.issn.1671-5411.2018.02.011.
33. Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention.
2022;18(2):e103-23. doi: 10.4244/eij-d-21-01034.
Journal of Emergency Practice and Trauma
Volume 10, Issue 2
July 2024
Pages 111-117

  • Receive Date 13 May 2025
  • Revise Date 04 July 2025
  • Accept Date 04 August 2025

Home

Editor-in-Chief: Shahrad Tajoddini, MD

Guide for Authors

Submit Manuscript

Reviewers

Contact Us

Editorial board